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More than 50% of prostate tumors have a chromo-
somal rearrangement resulting in aberrant expres-
sion of an oncogenic ETS family transcription factor.
However, mechanisms that differentiate the function
of oncogenic ETS factors expressed in prostate tu-
mors from non-oncogenic ETS factors expressed in
normal prostate are unknown. Here, we find that
four oncogenic ETS (ERG, ETV1, ETV4, and ETV5),
and no other ETS, interact with the Ewing’s sarcoma
breakpoint protein, EWS. This EWS interaction was
necessary and sufficient for oncogenic ETS functions
including gene activation, cell migration, clonogenic
survival, and transformation. Significantly, the EWS
interacting region of ERG has no homology with
that of ETV1, ETV4, and ETV5. Therefore, this finding
may explain how divergent ETS factors have a com-
mon oncogenic function. Strikingly, EWS is fused to
various ETS factors by the chromosome transloca-
tions that cause Ewing’s sarcoma. Therefore, these
findings link oncogenic ETS function in both prostate
cancer and Ewing’s sarcoma.
INTRODUCTION
In 50%–70% of prostate tumors, a chromosomal rearrangement
results in fusion of a transcriptionally active promoter and 50 UTR
to the open reading frame of an ETS family transcription factor,
resulting in aberrant expression in prostate epithelia (Tomlins
et al., 2005, 2007). The most common fusion is TMPRSS2:ERG,
occurring in approximately one-half of prostate tumors. ETV1
and ETV4 rearrangements occur in an additional 5%–10% of
tumors. Expression of ERG, ETV1, and ETV4 in prostate cells
is oncogenic, particularly when coupled with a second mutation
activating the PI3K/AKT or androgen receptor pathways (Aytes
et al., 2013; Baena et al., 2013; Carver et al., 2009; King et al.,
2009; Zong et al., 2009). Fusion transcripts involving other ETSCell Rep
This is an open access article under the CC BY-Ngenes (ETV5, FLI1, EHF, ELF2, ELK4, and ETV6) have been iden-
tified at low frequency (<2%), but it is not clear if these are onco-
genic or passenger mutations (Rickman et al., 2009; Robinson
et al., 2015). Although significant progress has been made in
understanding the oncogenic gene targets of ERG, ETV1, and
ETV4, the molecular mechanisms used by these three ETS tran-
scription factors to activate transcription of these target genes
are largely unknown. Furthermore, although these rearrange-
ments tend to be mutually exclusive (Svensson et al., 2011), it
is not clear if ERG, ETV1, and ETV4 utilize a common molecular
mechanism to promote prostate cancer.
The human genome encodes 28 ETS factors, and these are
extensively co-expressed, with at least 15 present in any individ-
ual cell type (Hollenhorst et al., 2004). ETS proteins share a highly
conserved ETS DNA binding domain and can be divided based
on similarities in this domain into subfamilies of no more than
threemembers each (Hollenhorst et al., 2011b).Within a subfam-
ily, amino acid homology extends across the entire protein, but
between subfamilies, the only homology is in the ETS DNA bind-
ing domain. ETV1, ETV4 (PEA3), and ETV5 comprise the PEA3
subfamily, but ERG is in a distinct subfamily, and therefore,
outside of the DNA binding domain, ERG has no amino acid
sequence similarity with ETV1, ETV4, and ETV5. Instead, ERG
is homologous with FLI1 and FEV, which have no clear roles in
prostate cancer. These sequence comparisons make it difficult
to predict a conserved functional mechanism through which
ERG, ETV1, and ETV4 promote prostate cancer that would
not also extend to the non-oncogenic ETS factors normally
expressed in prostate cells.
Oncogenic ETS proteins are known to promote cell migration,
invasion, and epithelial-mesenchymal transition (EMT) when
overexpressed in prostate epithelial cells (Tomlins et al., 2008;
Wu et al., 2013). By directly comparing overexpression of multi-
ple ETS factors in RWPE1 immortalized-normal prostate epithe-
lial cells, we previously demonstrated that only ERG, ETV1,
ETV4, and ETV5, but not FLI1 or other ETS proteins, promote
cell migration (Hollenhorst et al., 2011a), indicating that these
four ETS proteins share a common biological function that is
unique in the ETS family. These ETS proteins activated transcrip-
tion of cell migration genes by binding cis-regulatory sequencesorts 17, 1289–1301, October 25, 2016 ª 2016 The Author(s). 1289
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
that have neighboring ETS and AP-1 transcription factor binding
sites. However, this ETS/AP-1 binding is not specific to ERG,
ETV1, ETV4, and ETV5, because ETS1 can also bind ETS/AP-1
sequences and activate transcription of cell migration genes in
KRAS mutant cancer cells (Plotnik et al., 2014). Therefore the
molecular mechanism behind the specific biological function of
ERG, ETV1, ETV4, and ETV5 in prostate cells is unknown.
Prostate cancer is not the only malignancy caused by ETS
gene rearrangements. Ewing’s sarcoma is caused by chromo-
somal translocations involving one of five different ETS genes.
Prostate cancer chromosomal rearrangements generally pro-
mote expression of full-length or N-terminally truncated ETS pro-
teins (Clark et al., 2007). In contrast, the oncogenic product of an
Ewing’s sarcoma translocation is a fusion protein consisting of
an N-terminal domain of the RNA binding protein EWS fused to
a C-terminal region of an ETS protein (Delattre et al., 1992; Patel
et al., 2012). In this fusion oncoprotein, the N terminus of EWS
contributes a strong transcriptional activation domain, and the
C terminus of the ETS protein contributes the ETS DNA binding
domain, both of which are necessary for transformation of
Ewing’s sarcoma cells (May et al., 1993). Interestingly, the five
ETS genes involved in Ewing’s sarcoma fusions (FLI1, ERG,
FEV, ETV1, and ETV4) partially overlap with those rearranged
in prostate cancer. However, the most common Ewing’s fusion
is EWS:FLI1 (85%), and FLI1 has not been shown to drive pros-
tate tumorigenesis and does not promote prostate cell migration
(Hollenhorst et al., 2011a). Furthermore, there is no known
connection between the molecular mechanism of prostate can-
cer ETS rearrangements and Ewing’s sarcoma fusion proteins.
This study investigated the role of the wild-type EWS protein in
the oncogenic mechanism of ETS genes rearranged in prostate
cancer. EWS was found to interact specifically with the ETS pro-
teins ERG, ETV1, ETV4, and ETV5. This interaction occurred
both in cell lines and between purified proteins, indicating it is
direct. Fusion of the EWS N terminus with any ETS protein pro-
moted prostate cell migration, indicating that this interaction is
sufficient for an oncogenic phenotype. Furthermore, using both
a knockdown of EWS and a point mutation in ERG that fails to
interact with EWS, we demonstrate that the EWS-ETS interac-
tion is critical for oncogenic ETS proteins to activate gene
expression and drive cell migration and transformation in pros-
tate cells. Activation of gene expression via ETS and EWS
occurred through both ETS/AP-1 and GGAA-repeat cis-regula-
tory sequences. The necessity of EWS was specific to cell lines
that express oncogenic ETS proteins, indicating that therapeutic
strategies to inhibit this interaction may result in few side effects.
These data suggest that a protein-protein interaction with EWS
defines the specific oncogenic function of the ETS family tran-
scription factors that drive prostate tumorigenesis and sets the
stage for future work to further define this interaction in vivo
and in human tumors.
RESULTS
EWS Interacts Specifically with ETS Transcription
Factors that Promote Prostate Cancer
The EWS protein is fused to ETS transcription factors in Ewing’s
sarcoma, but the oncogenic role for wild-type EWS is less clear.1290 Cell Reports 17, 1289–1301, October 25, 2016To test if EWS naturally interacts (absent fusion) with any ETS
protein, we immobilized 21 purified full-length ETS proteins,
representing every ETS subfamily, on beads, and we used these
for affinity purification of interacting partners from PC3 prostate
cancer cell nuclear extract. An immunoblot indicated that four of
these 21 ETS proteins strongly and specifically interact with EWS
(Figure 1A). Surprisingly, these four ETS proteins (ERG, ETV1,
ETV4, and ETV5) cannot be grouped by common sequence
but are linked by a common biological function: the ability to pro-
mote prostate cancer. This indicates that an interaction with
EWS could define a common molecular mechanism for prostate
cancer ETS oncoproteins.
To test if this interaction occurs in cancer cells, two prostate
cancer cell lines that overexpress an oncogenic ETS factor
were examined. VCaP cells have a TMPRSS2:ERG fusion
(Tomlins et al., 2005), and immunoprecipitation with an anti-
ERG antibody enriched for EWS (Figure 1B). PC3 cells overex-
press ETV4 (Hollenhorst et al., 2011c), and immunoprecipita-
tion with an anti-ETV4 antibody also enriched for EWS
(Figure 1C). Reverse co-immunoprecipitation with anti-EWS
antibody enriched for ERG (Figure 1B) and ETV4 (Figure 1C).
EWS also co-immunoprecipitated with ERG in an ERG-positive
primary prostate tumor (Figure 1D). To further validate the
in vivo interaction, both ERG and EWS genomic occupancy
was mapped in VCaP cells by chromatin immunoprecipitation
sequencing (ChIP-seq). ERG-bound regions showed significant
overlap with those identified in previous studies (Chng et al.,
2012; Yu et al., 2010) and were enriched for ETS binding sites
and histone H3 acetylation (Figures S1A and S1B). EWS co-
occupied 1,242 of these ERG-bound genomic regions (Fig-
ure 1E; Table S1), a greater than 3-fold enrichment over the
random expectation (p < 0.0001). Together, these data indicate
that oncogenic ETS proteins interact with EWS in prostate
cancer cells.
To test if the interaction between oncogenic ETS proteins and
EWS is direct, glutathione S-transferase (GST)-tagged full-length
EWS was purified from bacteria (Figure 1F) and mixed with
beads bound to purified full-length ETS proteins. ERG, ETV1,
ETV4, and ETV5 interacted with purified EWS, while the close
ERG homolog, FLI1, did not (Figure 1G). The interaction of
ETV1 with EWS was dramatically weaker than ERG, ETV4, or
ETV5, indicating that the ETV1-EWS interaction may require
additional partner proteins or posttranslational modifications.
Together, these data suggest a direct and specific interaction
between EWS and oncogenic ETS proteins.
Fusion with EWS Allows Any ETS Factor to Function like
the Four Oncogenic ETS
Overexpression of ERG, ETV1, ETV4, and ETV5, but no other
ETS proteins, promotes migration of the normal prostate cell
line RWPE1 (Hollenhorst et al., 2011a). Strikingly, even the close
ERG homolog FLI1 lacks this function. However, in Ewing’s sar-
coma, both FLI1 and ERGare oncogenic when fused to theN ter-
minus of EWS due to a chromosomal rearrangement. To test
if fusion of EWS could impart an oncogenic function on ETS pro-
teins expressed in prostate cells, we compared full-length wild-
type versions of seven ETS proteins to the same proteins
N-terminally fused to amino acids 1–264 of EWS. To avoid
Figure 1. EWS Interacts Specifically with Oncogenic ETS Proteins
(A) Indicated purified His-ETS proteins were immobilized, incubated with PC3 nuclear extract, and washed. EWS binding was visualized by immunoblot (top) and
ETS proteins by Ponceau stain (bottom).
(B–D) Co-immunoprecipitation and reverse co-immunoprecipitation with indicated antibodies on extracts from VCaP (B) and PC3 (C) cell lines or a primary
prostate tumor (D). Immunoglobulin G (IgG)-coated beads (beads) were used as control.
(E) Overlap of bound regions identified by ChIP-seq in VCaP cells. Parenthesis indicates random prediction based on 125,000 possible binding sites.
(F) SDS-PAGE stained with Coomassie brilliant blue showing GST and GST-EWS purified from bacteria.
(G) Interaction of purified GST-EWS with purified, immobilized His-ETS proteins shown by anti-EWS immunoblot (top). His-ETS proteins were visualized by
Ponceau stain (bottom).
See also Figure S1 and Table S1.super-physiological expression levels, the cytomegalovirus
(CMV) promoter in the viral expression vector was replaced
with the weaker HNRNPA2B1 promoter, a promoter that drives
ETS expression in some prostate tumor rearrangements (Tom-
lins et al., 2007). ERG expression from this vector was lower
than ERG expression in VCaP cells or from a CMV vector (Fig-
ure S2A) but still caused a more than 3-fold increase in RWPE1
cell migration (Figure 2A). In contrast, expression of six non-
oncogenic ETS proteins, including FLI1, did not significantly
change cell migration (Figures 2A and S2B). Expression of the
EWS N terminus by itself had no effect on cell migration, but
every EWS-ETS fusion protein tested caused significant in-
creases in cell migration. None of the EWS-ETS fusion proteins
accumulated to appreciably higher levels in the cell than the
ETS protein alone (Figure 2B). In Ewing’s sarcoma fusions, the
N terminus of ERG or FLI1 is removed and replaced by the N ter-
minus of EWS. To test if this truncation of the ETS N terminus
affected cell migration, we also tested EWS-NtermDERG and
EWS-NtermDFLI1 constructs analogous to the fusion proteins
found in Ewing’s sarcoma. These EWS-NtermDETS constructs
drove cell migration to the same extent as EWS-ETS constructs
(Figures 2A and 2B). Therefore, an obligate interaction with
the EWS N terminus is sufficient to allow an ETS protein to act
like an oncogenic ETS factor.To test if this role of EWS was limited to cell migration, a sec-
ond phenotype, clonogenic survival, was assayed (Figure 2C).
ERG expression alone caused little increase in clonogenic sur-
vival of RWPE1 cells. Previous reports indicate that ERG and
activated AKT are both required for tumor formation (Carver
et al., 2009; King et al., 2009). Expression of myristoylated AKT
increased AKT activation but alone had little affect on clonogenic
survival. However, expression of both ERG and myristoylated
AKT together resulted in a dramatic increase in clonogenic sur-
vival (Figure 2C). Similar to the cell migration phenotype, FLI1
expression with activated AKT caused significantly lower in-
creases in clonogenic growth than ERG with activated AKT,
but EWS fused to FLI1 was similar to ERG (Figure 2C). Both
cell migration and clonogenic growth assays indicate that the
EWS interaction is sufficient to allow non-oncogenic ETS pro-
teins to function like ERG.
Identification of EWS-ETS Interaction Domains
To identify the region of ERG that interacts with EWS, various
ERG truncations and deletions were purified and tested for the
EWS interaction in PC3 nuclear extract (Figure 3A). A deletion
of the C terminus of ERG after amino acid 391 resulted in a
loss of EWS binding. However, a truncated ERG containing
amino acids 275–455 retained EWS binding. Therefore, theCell Reports 17, 1289–1301, October 25, 2016 1291
Figure 2. EWS-ETS Fusions Drive Prostate Cell Migration
(A) A transwell assay using RWPE1 cells stably expressing FLAG-tagged versions of the indicated ETS protein, EWSN terminus (1–264) alone, or EWSN terminus
fused to an ETS. The fraction of migrated cells is shown relative to RWPE1 with empty vector as the mean and SEM of three replicates. p value (*p < 0.05, **p <
0.01, ***p < 0.001) were obtained by t tests comparing EWS-ETS to corresponding ETS.
(B) Immunoblots indicate expression of indicated proteins with tubulin as a loading control.
(C) Immunoblot of indicated proteins (top). Clonogenic survival of RWPE1 cells expressing the indicated ETS and/or myristoylated AKT shown bymean and SEM
of colony number (middle) or representative image (bottom).
See also Figure S2.region of ERG, C-terminal to the ETS domain, between amino
acids 391 and 455, was necessary for the EWS interaction.
A deletion analysis of ETV5 identified a region necessary for
EWS interaction that was N-terminal to the ETS domain span-
ning amino acids 357–368 (Figure 3B). This region of ETV5 has
high homology to PEA3 subfamily proteins ETV1 and ETV4 but
no homology to any region of ERG (Figures S3A and S3B). Simi-
larly, the EWS interacting region of ERG had no homology with
any region of ETV1, ETV4, or ETV5, indicating that ERG and
PEA3 proteins interact with EWS through distinct interaction do-
mains. The EWS interaction region of ERG has 75% identity with
FLI1 (Figure S3A), which did not physically interact with EWS
(Figure 1A). To identify the difference that allows ERG, but1292 Cell Reports 17, 1289–1301, October 25, 2016not FLI1 to bind EWS, point mutations were created in ERG
in amino acids that differ from FLI1 between 391 and 455. Two
of these ERGpointmutants were purified and tested for the inter-
action with EWS from PC3 cell nuclear extract (Figure 3C). One
mutant, ERG P436A, eliminated the EWS interaction. Purified
EWS protein was also used to show that ERG 1–391 and ERG
P436A fail to directly interact with EWS (Figure 3D). To test if
the P436A mutation disrupted the ERG-EWS interaction in cells,
FLAG-ERG and FLAG-ERG P436A were expressed in RWPE1
cells and immunoprecipitated with anti-ERG antibody. Only
ERG, and not ERG P436A, interacted with EWS (Figure 3E).
Therefore ERG P436 is required for the EWS interaction both
in cells and in vitro.
Figure 3. Identification of the EWS Interaction Domains
(A) A schematic of ERG protein showing the two known structured domains: pointed (PNT) and ETS DNA binding (ETS) (top). Indicated ERG constructs with a
N-terminal His tag were immobilized to beads, mixed with PC3 nuclear extract, and washed. EWS binding was visualized by immunoblot (middle). Ponceau stain
of the same blot shows the amount of His-ERG present (bottom).
(B) ETV5 has one known structured domain (ETS). The region of ETV5 that binds to EWS was mapped as in (A).
(C) EWS interaction with ERG as in (A), but with wild-type (WT) ERG or indicated ERG point mutants.
(D) Interaction of purified GST-EWS with indicated purified and immobilized His-ERG proteins. EWS binding is shown by immunoblot (top). His-ETS protein was
visualized by Ponceau stain (bottom).
(E) Nuclear extracts prepared from RWPE1 cells stably expressing FLAG-ERG or FLAG-ERG P436A were immunoprecipitated (IP) with anti-ERG antibody (lanes
2 and 3) or bead-only control (lane 1) followed by immunoblotting for EWS or FLAG.
See also Figure S3.The Interaction with EWS Is Necessary for Oncogenic
ETS-Mediated Phenotypes, Including Tumorigenesis
Four oncogenic ETS proteins uniquely promote prostate cell
migration (Hollenhorst et al., 2011a) and uniquely interact with
EWS (Figure 1A). To test if the EWS interaction is required for
the cell migration function, the ability of ERG and ERG P436A
to promote migration of RWPE1 cells was compared. Despite
being expressed at the same level, ERGpromoted cell migration,
and ERG-P436A inhibited cell migration (Figures 4A and S4A).
This indicated not only that the EWS interaction was necessary
for this ERG function but also that loss of the EWS interaction
reversed ERG’s function. A similar result was observed in the
clonogenic growth assay, where the P436A mutation abrogated
the ability of ERG to promote colony formation (Figure 4B).
Neither ERG nor ERG P436A expression altered cell proliferation
when plated at higher density (Figure S4B). To verify the neces-
sity of EWS for an oncogenic ETS to promote cell migration, EWS
was depleted from two prostate cancer cell lines, PC3 andDU145, using two independent small hairpin RNAs (shRNAs)
(Figure 4C). PC3 prostate cancer cells migrate due to overex-
pression of the oncogenic ETS ETV4 (Hollenhorst et al.,
2011c), while DU145 prostate cancer cells migrate due to a
KRAS gene rearrangement and do not express any of the onco-
genic ETS (Selvaraj et al., 2014; Wang et al., 2011). EWS knock-
down significantly decreased migration of PC3 cells, but not
DU145 cells (Figures 4C and S4C). This indicates that EWS is
required for cell migration in a cell line that expresses an onco-
genic ETS, but not for cell migration in general. EWS knockdown
had no effect on PC3 or DU145 cell proliferation (Figure S4D). To
further confirm the specificity of EWS for oncogenic ETS-
induced cell migration, we used the RWPE1 system. We have
previously shown that either ERG or KRAS overexpression
causes RWPE1 cells to migrate by activating a similar gene
expression program (Hollenhorst et al., 2011a; Selvaraj et al.,
2014). The necessity of EWS for this migration was compared
by EWS knockdown in RWPE1-ERG and RWPE1-KRAS cells.Cell Reports 17, 1289–1301, October 25, 2016 1293
Figure 4. EWS Is Necessary for Oncogenic ETS-Mediated Phenotypes
(A) Transwell migration of RWPE1 cells expressing FLAG-ERG or FLAG-ERG P436A is shown relative to RWPE1 cells with empty vector as the mean and SEM of
three biological replicates (top). Immunoblot of cells used in transwell assay (bottom).
(B) Mean and SEM of colony number and representative images of clonogenic growth of same lines used in (A); n = 3.
(C) Transwell migration of PC3 or DU145 prostate cancer cells stably expressing the indicated shRNA is shown relative to the negative control shRNA (targeting
luciferase) as mean and SEM; n = 3 (top). Immunoblots of lines used in the transwell assay are shown (bottom).
(D) Migration as in (C) but using RWPE1 cells overexpressing ERG or KRAS as indicated.
(E) Migration of PC3 cells as (C) with or without EWS shRNA and 3xHA-EWS overexpression is indicated.
(F) Soft-agar growth fromPC3 (n = 3), MDA-PCa-2B (n = 2), or VCaP (n = 2) cells with EWS knockdown as in (C) or as shown. Colonies present after 10 days relative
to those expressing the control shRNA are shown as mean and SEM.
All p values (*p < 0.05, **p < 0.01, ***p < 0.001, ns > 0.05) were obtained by t test (compared to control in the same cell line,) unless noted by a bracket. See also
Figure S4.EWS knockdown significantly reducedmigration in ERG-overex-
pressing cells, but not the KRAS-overexpressing cells (Figures
4D and S4C). EWS knockdown had no effect on RWPE1-ERG
or RWPE1-KRAS cell proliferation (Figure S4E). To show speci-
ficity, the EWS knockdown phenotype was rescued by EWS
overexpression (Figures 4E and S4F). To extend these findings
to another oncogenic ETS function, roles in anchorage-indepen-
dent growth were tested. The oncogenic ETS protein ETV4 is
required for anchorage-independent growth of PC3 prostate
cancer cells (Hollenhorst et al., 2011c), and loss of EWS signifi-
cantly inhibited growth of PC3 cells in soft agar (Figures 4F1294 Cell Reports 17, 1289–1301, October 25, 2016and S4G). ETV1 and ERG are overexpressed in MDA-PCa-2B
and VCaP cell lines, respectively, due to chromosomal rear-
rangements like those observed in patient tumors (Tomlins
et al., 2007). EWS knockdown reduced soft-agar growth of
both of these cell lines (Figures 4F and S4G). Together, these
data show that the EWS interaction is responsible for common
biological functions of oncogenic ETS proteins.
To directly test the role of the EWS-ERG interaction in tumor
growth, we employed the established subcutaneous xenograft
tumor growth model (Shaw et al., 2010). Since ERG accelerates
tumor formation when expressed in prostate cells with activated
Figure 5. Tumor Growth Promoted by ERG Requires the EWS Interaction
(A) Immunoblots show expression of 3xFlag-ERG or phosphorylated AKT (pAKT) in RWPE1 cells expressing the indicated constructs.
(B) Cells from (A) were co-injected with cancer associated fibroblasts into the flanks of immunocompromisedmice and tumor volumewasmeasured by caliper at
the indicated time points. Mean and SEM of six (ERG P436A/Myr-AKT) or twelve (all others) experiments are shown.
See also Figure S5.Akt signaling, we combined RWPE1 prostate cells stably ex-
pressing ERG, myristoylated AKT (myr-AKT), or both with can-
cer-associated fibroblasts subcutaneously into the flank of
immunocompromisedmice. ERG expression and AKT activation
were confirmed by immunoblot (Figure 5A). An RWPE1 vector-
only control formed no tumors, while RWPE1 cells expressing
ERG or myr-AKT alone formed small masses that became stag-
nant after an initial growth phase between weeks 1 and 4 (Fig-
ure 5B). RWPE1 cells expressing both ERG andmyr-AKT formed
significantly larger tumors than cells expressing myr-AKT alone
(p = 0.043, ANOVA, n = 12; Figure 5B), and these tumors
continued to grow throughout the experiment, confirming that
ERG is oncogenic. Importantly, the P436A point mutation of
ERG abrogated this oncogenic function (Figures 5B and S5A).
Although tumors expressing ERG and ERG-P436A had similar
histology, there was a trend toward less proliferation in ERG-
P436A tumors (Figure S5B). Together, these data indicate that
the EWS interaction is required for the tumor-promoting function
of ERG.
EWS Acts as a Co-activator for ERG
To activate gene expression, transcription factors generally bind
to cis-regulatory elements and then recruit co-activator proteins
that promote transcription. If EWS is recruited by ERG to target
sites as a co-activator, we would expect the EWS binding
mutant, ERG P436A, to bind target sites, but fail to recruit
EWS resulting in loss of transcriptional activation. To test this
hypothesis, ERG and ERG P436A were expressed in RWPE1
cells and genomic occupancy of ERG and EWS was assayed
by ChIP. Six ERG target sites previously identified by ChIP-
seq in this cell line (Hollenhorst et al., 2011a) showed very
similar enrichment for both ERG and ERG P436A (Figure 6A),
but EWS occupancy of the same genomic sites was signifi-
cantly diminished by the ERG P436A mutant (Figure 6B). To
test this if this pattern extended genome-wide, we first per-formed ERG ChIP-seq in RWPE1-ERG cells to identify 1,901
ERG-bound regions. We then did independent ERG and EWS
ChIP-seq in both ERG wild-type, and ERG-P436A expressing
RWPE1 cells. In ERG-P436A-expressing cells, ERG enrichment
actually increased compared to wild-type ERG, but EWS
enrichment decreased (Figures 6C, S6A, and S6B). Peak calling
indicated that a subset of ERG binding sites were occupied by
EWS (Figure S6A). However, most of the ‘‘ERG alone’’ binding
sites displayed EWS enrichment compared to neighboring chro-
matin, and this EWS enrichment also decreased in the ERG-
P436A mutant (Figure S6A). It is possible that many of these
sites are false negatives for EWS peak calling due to the diffi-
culty of ChIP when a factor does not directly bind DNA.
Together, these data indicate that the P436A mutation in ERG
does not disrupt ERG chromatin occupancy but results in
decreased EWS recruitment.
To test if loss of EWS from chromatin lowered gene expres-
sion, levels of two ERG target genes, ARHGAP29 and PIK3AP1,
was compared by qRT-PCR. Both were significantly lower when
ERG P436A was expressed compared to ERG (Figure 6D). To
extend this comparison genome-wide, we profiled in triplicate
the transcriptome of RWPE1 cells expressing vector only,
ERG, ERG-P436A, or ERG with an shRNA knockdown of EWS.
680 genes were significantly activated in the ERG-expressing
cells compared to vector-only (2-fold or higher and adjusted
p value < 0.05). ERG-activated genes were highly enriched
for known ERG-regulated processes such as cellular migration
and cellular adhesion and were enriched for neighboring ERG
ChIP-seq binding sites (Figures S6C and S6D). ERG-activated
transcripts were present at significantly lower levels in cells ex-
pressing ERG P436A or in ERG-expressing cells lacking EWS
(Figure 6E; Table S2) than in cells expressing wild-type ERG
alone. In fact, 86%of ERG-induced genes showed lower expres-
sion in ERG-P436A and 87% were lower when ERG was ex-
pressed with EWS knockdown (Figure S6E). Together, theseCell Reports 17, 1289–1301, October 25, 2016 1295
Figure 6. ERG Recruits EWS to Enhancers, Increasing Gene Expression
(A) Chromatin immunoprecipitation (ChIP) with anti-ERG antibody in RWPE1 cells expressing ERG or ERG-P436A. Enrichment indicates copies of indicated locus
in the immunoprecipitate compared to a negative control locus (first two bars). Values are shown as mean and SEM (n = 3). Loci are labeled by the nearest gene.
(B) ChIP as in (A), but with anti-EWS antibody.
(C) Ratio of ChIP-seq reads to input reads at 1,901 ERG-bound regions upon replicate ERG ChIP-seq or EWS ChIP-seq in RWPE1 cells expressing ERG or
ERG-P436A.
(D) mRNA level of two ERG target genes by qRT-PCR in RWPE1 cells expressing the indicated construct shown relative to cells with empty vector. Values are
shown as mean and SEM (n = 3).
(E) Box-plots show expression of 680 genes significantly activated by ERG in RWPE1 compared to vector only. Box showsmedian (25th and 75th percentiles), and
bars encompass all values except outliers.
All p values (*p < 0.05, **p < 0.01, ***p < 0.001) were obtained by t test. See also Figure S6 and Table S2.findings indicate that EWS acts as a co-activator for the majority
of ERG target genes.
Oncogenic ETS and EWS Can Activate Transcription
through Known Prostate Cancer and Ewing’s Sarcoma
Cis-Regulatory Sequences
We previously found that oncogenic ETS activate gene expres-
sion in prostate cells by binding cis-regulatory sequences con-
sisting of neighboring ETS and AP-1 transcription factor binding
sites, and these ETS/AP-1 sites occur near cell migration genes
(Hollenhorst et al., 2011a). In Ewing’s sarcoma, EWS-FLI1 acti-
vates transcription via cis-regulatory elements consisting of mi-
crosatellite repeats of the core ETS binding sequence, GGAA,
and these GGAA repeats regulate the expression of genes that
promote transformation and cancer cell survival (Gangwal
et al., 2008; Riggi et al., 2014). However, GGAA repeats have
not been identified as targets of oncogenic ETS factors in pros-
tate cancer. Interestingly, an unbiased search of over-repre-
sented sequences in regions bound by both ERG and EWS in
VCaP cells identified the GGAA repeat (Figure S1B). To expand
this finding, datasets of ERG-, ETV1-, and ETV4-bound regions1296 Cell Reports 17, 1289–1301, October 25, 2016in prostate cells were searched using the EWS-FLI1 position-
weight matrix with a statistical boundary requiring at least four
consecutive GGAA repeats (Table S3). Regions bound by ERG,
ETV1, and ETV4 were significantly enriched for GGAA repeats
compared to the random expectation (p < 0.0001 by c2). In
contrast, non-ETS transcription factors such as MYC and JunD
showed no enrichment for GGAA repeats (Table S3). To verify
that EWS is present at ERG-bound GGAA repeat targets
in VCaP cells, ChIP of ERG and EWS was assayed for enrich-
ment of two GGAA-repeat-containing enhancers (NEDD9 and
GALNT7) and two ETS/AP-1-containing enhancers (ARHGAP29
and PIK3AP1). All four enhancers showed enrichment of ERG
and EWS compared to a negative control locus (Figure 7A).
These data indicate that oncogenic ETS and EWS bind both
ETS/AP-1 sequences and GGAA repeats in prostate cells.
To test if oncogenic ETS activate via both ETS/AP-1 se-
quences and GGAA repeats in prostate cells, two luciferase
reporters were created, with one representing each type of
enhancer. An ETS/AP-1-containing enhancer of the FHL3 gene
was cloned upstream of a minimal promoter controlling lucif-
erase. Alternatively, seven consecutive copies of the sequence
Figure 7. ERG and EWS Activate Transcription via Both ETS/AP-1 and GGAA Repeat Sequences
(A) ChIP enrichment using anti-ERG and anti-EWS antibodies in VCaP cells at two enhancers with GGAA repeats and twowith ETS/AP-1 sequences compared to
a control locus. Values are mean and SEM of three replicates.
(B) Immunoblot from RWPE1 cells transfected with the indicated FLAG-tagged constructs.
(C) Ratio of firefly to renilla (control) luciferase in RWPE1 cells transfected with minimal promoter firefly reporter and indicated expression construct, normalized to
vector only. Values are mean and SEM (n = 3).
(D)As in (C), butwith sevencopiesofGGAAprior tominimalpromoter, except for last twocolumnswhichhavesevencopiesofGAGA (GGAAmutant). p values (*<0.05,
** < 0.01, *** < 0.001) by t test compare each ETS to FLI1, whereas p values denoted # compare mutant to wild-type reporter with the same ETS expressed.
(E) As in (D), except the reporter has a 474-bp region of an ETS/AP-1-containing enhancer present prior to the minimal promoter. The last two columns have the
single ETS sequence mutated from GGAA to GAGA.
(F) EWS and tubulin immunoblots of RWPE1 cells stably expressing the indicated shRNAs.
(G) Relative luciferase as in (D) in RWPE1 cells expressing either ERG or ETV4 and shRNAs shown in (F).
(H) As in (G), but with the ETS/AP-1 reporter.
(I and J) Relative luciferase expression from7xGGAAor theETS/AP-1 reporter in RWPE1 cells expressing the indicated version of ERGshown relative to vector only.
See also Table S3.
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GGAA were cloned upstream of the minimal promoter. These
two reporters, or the original minimal promoter vector, were
then co-transfected into RWPE1 cells along with constructs ex-
pressing FLAG-tagged versions of ETV1, ETV4, ETV5, ERG,
FLI1, and EWS-FLI1. Each of these proteins was expressed at
similar levels (Figure 7B). Expression of these proteins had no ef-
fect on the empty vector containing the minimal promoter alone
(Figure 7C), but activation was observed in the GGAA repeat re-
porter (Figure 7D) and the ETS/AP-1 reporter (Figure 7E). Muta-
tion of each GGAA repeat to GAGA or mutation of the single ETS
binding sequence in the ETS/AP-1 reporter eliminated activation
by ETV4 and ERG (Figures 7D and 7E), indicating that an ETS
binding sequence was required. Significantly, the four ETS pro-
teins that interact with EWS caused significantly more activation
of both reporters compared to FLI1, which does not interact with
EWS (Figures 7D and 7E). Furthermore, the fusion of EWS to FLI1
(EWS-FLI1) activated the reporters significantly more than FLI1
and to a similar extent as ERG. These data indicate that both
prostate cancer and Ewing’s sarcoma ETS oncoproteins can
activate through both ETS/AP-1 and GGAA repeat sequences.
We next tested if activation through ETS/AP-1 and GGAA-
repeat sequences required EWS. First, ERG and ETV4 activation
were tested in cell lines with EWS shRNA knockdowns (Fig-
ure 7F). Knockdown of EWS significantly decreased the activa-
tion of both ETS/AP-1 and GGAA-repeat reporters by both
ERG and ETV4 (Figures 7G and 7H). Second, the function of
the ERG P436A mutant, which does not interact with EWS,
was assayed. Compared to wild-type ERG, ERG P436A had a
decreased ability to activate both ETS/AP-1 and GGAA-repeat
reporters (Figures 7I and 7J). Interestingly, EWS shRNA, ERG
P436A, and FLI1 showed a similar 50% lower activation of
GGAA-repeat reporters compared to the ERG control (Figures
7D, 7G, and 7I), indicating that the difference between ERG
and FLI1 transcriptional activation could be the ability of ERG
to interact with EWS. Together, these data suggest that either
through fusion (Ewing’s sarcoma) or a protein-protein interaction
(prostate cancer), EWS works with oncogenic ETS proteins
to activate transcription of target genes via ETS/AP-1 and
GGAA-repeat sequences.
DISCUSSION
These findings indicate that the common molecular mechanism
of the ETS proteins that promote prostate cancer is an interac-
tion with EWS. EWS binding to oncogenic ETS proteins was
observed both in cells and using purified proteins, and this inter-
action was confined to four ETS family members: ERG, ETV1,
ETV4, and ETV5. EWS was necessary for multiple oncogenic
ETS functions, including transcriptional activation, cell migration,
clonogenic growth, and transformation, but EWSwas not neces-
sary in cell lines lacking oncogenic ETS expression. A point
mutant of ERG that failed to drive tumor growth was not defec-
tive in chromatin occupancy but lacked the ability to recruit
EWS as a transcriptional co-activator. In summary, these find-
ings reveal a highly specific protein-protein interaction neces-
sary for oncogenic ETS function.
The interaction of EWS with ERG, ETV1, ETV4, and ETV5 is
striking, because ERG shares no homology with ETV1, ETV4,1298 Cell Reports 17, 1289–1301, October 25, 2016and ETV5 apart from the ETS DNA binding domain, which is pre-
sent in all ETS proteins. Consistent with this, the regions of ERG
and ETV5 that we mapped as the EWS interaction domains had
no homology. This suggests that the EWS interaction with ERG
may have evolved separately and may occur through a different
interface compared to the interaction with ETV1, ETV4, and
ETV5. It would also be expected that the EWS interaction is
part of the normal biology of ERG, ETV1, ETV4, and ETV5 in
the cell types where these proteins are normally expressed. In
support of this idea, it has recently been shown that ETV1 and
EWS cooperate to activate FGF10 in developing limb buds
and that both ETV1 and EWS bind the FGF10 promoter (Yama-
moto-Shiraishi et al., 2014).
Our data indicate that ERG has an oncogenic function that
FLI1 lacks, because ERG interacts with EWS and FLI1 does
not. However, gene rearrangements involving FLI1 have been
identified at low frequency in prostate tumors (Cancer Genome
Atlas Research Network, 2015; Paulo et al., 2012). We offer
two possible explanations for this discrepancy. First, it is
possible that FLI1 rearrangements are passenger mutations
and not oncogenic. A recent study identified 3,106 different
fusion transcripts in 150 metastatic prostate tumors (Robinson
et al., 2015). Only one of these involved FLI1. There were 1,329
genes rearranged more often than FLI1 in these tumors, and it
is likely that many of these are passenger mutations. The second
explanation is that FLI1 is oncogenic but requires a mutational or
signaling background not present in our system. For example,
ERG requires PI3K/AKT activation to robustly promote tumori-
genesis (Figure 5). It may be that FLI1 requires activation of an
unidentified signaling pathway to have the same function.
The role of EWS in oncogenic ETS function is likely to extend
beyond roles in prostate cancer. In addition to an oncogenic
function in prostate cancer, ERG is important for survival of leu-
kemia cells (Tsuzuki et al., 2011), and ETV5 expression corre-
lates with cell invasion in endometrial carcinoma (Planaguma`
et al., 2005). ETV4 has been reported to promote multiple tumor
types, including colorectal, gastric, esophageal, ovarian, and
non-small cell lung cancers (Oh et al., 2012). ETV1 plays impor-
tant roles in melanoma, where 40%of tumors have copy gains of
the ETV1 gene (Jane´-Valbuena et al., 2010). In gastrointestinal
stromal tumors, the ETV1 protein is stabilized and cooperates
with KIT mutations for cell transformation (Chi et al., 2010).
Future work will be necessary to determine the importance of
EWS interactions with ETS proteins in these tumor types.
EWS belongs to the FET family, which includes three highly
conserved members: FUS, EWS, and TAF15 (Tan and Manley,
2009). Intriguingly, all three FET family proteins are fused to tran-
scription factors in cancer. These include EWS-ETS fusions in
Ewing’s sarcoma and TLS-ERG fusion in myeloid leukemia (Ar-
vand and Denny, 2001). In some cancers, the FET member in
the fusion appears interchangeable, as in TLS-CHOP or EWS-
CHOP fusions in myxoid liposarcoma, EWS-CHN or TAF15-
CHN fusions in myxoid chondrosarcoma, and EWS-CIZ and
TAF15-CIZ fusions in acute leukemia (Martini et al., 2002). In
every fusion, the N-terminal domain of the FET protein is fused
to a region of the transcription factor that includes the DNA bind-
ing domain. In the context of the fusion protein, the N-terminal
domain from the FET protein has a strong transcriptional
activation function. These fusions do not alter DNA binding
directly (May et al., 1993). However, a comparison of EWS-
FLI1 and FLI1 genomic occupancy identified novel EWS-FLI1
bound enhancers (Patel et al., 2012). This is attributed to the abil-
ity of the EWS activation domain to alter local chromatin struc-
ture and create new enhancers (Patel et al., 2012; Riggi et al.,
2014). Therefore it is interesting to postulate that the recruitment
of EWS to enhancer regions by ERG would have a similar func-
tion and may be responsible for chromatin changes mediated
by ERG (Elemento et al., 2012).
The wild-type EWS protein that interacts with ERG is multi-
functional. EWS can interact with RNA polymerase II (RNAPII),
heterogeneous nuclear ribonucleoproteins (A1, C1/C2, M and
U), splicing factors (TASR-1 and YB-1), and RNA helicases
(p68 and p72), suggesting roles in both transcription and in
RNA processing (Bertolotti et al., 1998; Chansky et al., 2001;
Pahlich et al., 2009; Yang et al., 1998, 2000). Accordingly, EWS
can act as a co-activator for transcription factors such as
OCT4, HNF4, YBX1, and ETV1 (Araya et al., 2003; Lee et al.,
2005; Park et al., 2013; Yamamoto-Shiraishi et al., 2014) and
as an alternative splicing factor (Paronetto et al., 2011, 2014).
EWS-FLI1 has also been shown to alter splicing patterns (Selva-
nathan et al., 2015). It will be interesting to learn if the ETS factors
that are rearranged in prostate cancer also have roles in RNA
processing via EWS.
The ability of EWS to bind to, and function with, the ETS
proteins that are expressed due to chromosomal rearrange-
ments in prostate cancer indicates that this interaction is a
key to oncogenic function. As such, EWS and the EWS-
ETS interaction represent a highly specific target for prostate
cancer treatment.
EXPERIMENTAL PROCEDURES
Protein Purification
ETS proteins were purified as described previously (Selvaraj et al., 2015). In
brief, sequence verified constructs were cloned into pET28a (Novagen), ex-
pressed in Escherichia coliBL21 pRIL, and purified using Ni-NTA agarose resin
(QIAGEN). pGEX-6p-2-GST-EWS (Pahlich et al., 2009) was obtained from
Addgene (plasmid 46384). GST-EWS protein was expressed in BL21 pRIL,
induced with IPTG (0.5 mM) at 22C for 12–14 hr, and lysed by sonication in
extraction buffer (50 mM Tris-HCl [pH 7.4], 250 mM NaCl, 5 mM EDTA,
50 mM NaF, and 1% Nonidet P-40, 2 mM PMSF, 10% glycerol, and 30 mg
lysozyme). Glutathione magnetic beads (Pierce) were added to the lysate,
washed with GST wash buffer (125 mM Tris [pH 8.0] and 150 mM NaCl), and
eluted (50 mM reduced glutathione in GST wash buffer).
Reporter Assay
The 474-bp (chromosome 1 [chr1]: 38465034–38465507, hg19) FHL3
enhancer was cloned into firefly luciferase reporter pGL4.25 (Promega). For
the ETS site mutant, a sequence at position chr1: 38465405–38465402 was
changed from GGAA to GAGA using standard methods. The GGAA repeat re-
porter was created by annealing cDNA oligonucleotides (described in Supple-
mental Experimental Procedures) containing seven tandem repeats of GGAA
or GAGA and cloning into pGL4.25. A dual luciferase reporter assay (Promega)
measured luciferase activity as described previously (Plotnik et al., 2014).
Firefly luciferase values were normalized to renilla values.
RNA, Protein, and Affinity Purification from Cell Extracts
Antibodies for immunoblotting were ERG (CM 421, Biocare), EWS (sc-28327,
Santa Cruz Biotechnology), ETV4 (ARP32263_P050, Aviva Systems Biology),
pAKT (#4060, Cell Signaling Technology), tubulin (T9026, Sigma), and FLAG(F1804, Sigma). Total protein extract from equal number of cells were sepa-
rated on SDS-PAGE gels and immunoblotted using standard procedures.
RNA levels were measured by reverse transcription followed by qRT-PCR
with standard curves as described previously (Hollenhorst et al., 2011a).
RNA levels were normalized to 18S rRNA. Purified His-tagged proteins were
bound to Ni beads and incubated with PC3 cell extract. For more information
and oligo sequences, see Supplemental Experimental Procedures.
ChIP, ChIP-Seq, and RNA Seq
ChIP of indicated proteins was performed from VCaP and RWPE1 cells as
described previously (Hollenhorst et al., 2011a) using the same antibodies
described for immunoblotting, with slight modifications. Total RNA from three
biological replicates of RWPE1 cells expressing vector, ERG-WT, ERG-P436A,
or ERG-WT with EWS knockdown shRNA was isolated and sequenced
independently. For further information, see Supplemental Experimental
Procedures.
Viral Transductions and Cell Line Assays
VCaP and PC3 cell lines were authenticated within 6 months of use by a
PowerPlex 16HS assay (Promega). RWPE1 and RWPE-KRAS (RWPE2) lines
were obtained from ATCC and passaged less than 25 times. All lines were
cultured according to ATCC guidelines. Retroviral vectors stably overex-
pressed proteins and lentiviral vectors provided stable shRNA expression.
Migration and anchorage-independent growth assays were performed
as described previously (Hollenhorst et al., 2011c), with modifications. For
more information, see Supplemental Experimental Procedures.
In Vivo Xenograft Tumor Growth Model
All animal protocols described in this study were approved by the Institutional
Animal Care and Use Committee (IACUC) at the Indiana University School of
Medicine. 2 3 106 RWPE1 epithelial cells expressing ERG, activated Akt
(Myr-Akt), both ERG and Akt (ERG/Myr-Akt), mutant ERG with Akt (P436A/
Myr-Akt), or vector control (all as described above) were combined with an
equal volume of Matrigel and 0.5 3 106 cancer-associated fibroblast cells
and injected subcutaneously on the flanks of nude mice. Tumors were
measured weekly with calipers and tumor volume was calculated as the vol-
ume of a spheroid using the formula: volume = length 3 width 3 height 3
0.5236. Controls included each epithelial cell line without fibroblasts and
C4-2 prostate cancer cells with cancer associated fibroblasts (CAFs). Upon
completion of the experiment after 8 weeks, all tumorswere harvested, verified
as tumor, and processed for histology (10% buffered formalin, processing
through a gradient of ethanol and xylene and embedding in paraffin, and
then sectioning and H&E staining).
Statistical Analysis
Student’s t test was applied to data with at least three independent biological
replicates to calculate significance. Ac2 test with Yates correction was applied
for ChIP-seq analysis. Benjamini-Hochberg correction was used to calculate
adjusted p value for differential gene expression analysis.
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